| Catalog No. | HB823016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Interferon alpha/beta receptor 1, Cytokine receptor family 2 member 1, Cytokine receptor class-II member 1, CRF2-1, IFN-R-1, IFNAR1, IFNAR, IFN-alpha/beta receptor 1, Type I interferon receptor 1 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P17181 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -281°C. |
|---|
| Alternate Names | MDX-1333,MEDI-546,CAS:1326232-46-5 |
|---|
| Background | Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
